Our result of 34% CEA positive pT2–4 cancers is in the lower range of previous studies and very similar to the 30% that we previously observed in a partially overlapping set of pT2–4 carcinomas in a study on over 15 000 tumours from 120 different tumour entities (manuscript submitted). This evidence concerns the gene CEACAM5 and cancer.